The New Medical Device Regulation (MDR) comes into force today, 26th May 2021 for EU Member States.
This will replace the old Medical Device Directive (MDD) and governs the production and distribution of medical devices in Europe.
As these regulations did not take effect during the transition period, they were not EU law automatically retained by the EU Withdrawal Agreement Act and will therefore not automatically apply in Great Britain. This means that the provisions contained within the EU MDR will not be transposed into law in Great Britain and will not be implemented in Great Britain.
Of course, we are pleased to say that here, at Polyco Healthline, all our medical devices are in line with the new MDR and we are ready to help you navigate the new regulations.
It is set to have an affect upon many different companies and industries as some products which do not have an intended medical purpose will now need to be compliant with the regulations. This breakdown will clearly show the differences between the old Medical Devices Directive (MDD) and those which will come into full now.
What Has Changed?
Several updates and changes have been made to regulations covering Medical Devices. The new MDR is a lot more comprehensive than the old MDD.
While nothing from the old MDD has been lost, a lot has been added in, including:
Changes to quality and risk management procedures
Changes to device classification
Changes to the notified bodies involved
Changes to the post-market surveillance and vigilance
The goal, of course, is to ensure that medical devices which make it to the public are consistently high quality and fit for their intended purposes!
Our products have not changed but you will notice changes in the labelling of the products.
Quality, Risk, And Classification
Companies which produce devices or products covered by the new regulation will now be required to create a documented risk management plan. This plan should identify potential risks associated with the use of the device, and evaluate the information gained from the production phase to do so. As a part of this, manufacturers will also be required to create a post-market surveillance plan.
The classification of medical devices will still be based upon level of risk with devices being classed as class I, II, or III (or A, B, or C for in vitro medical devices). Anything above class I or A will require approval from the official “Notified Bodies (including class I sterile and class I metrology/measuring and class I reusable), while Class I and A devices can be subject to self-assessment.
These changes will be subject to conformity assessment and random auditing.
Notified Bodies, Pre-Market Checks, And Traceability
Manufacturers will not only be affected by changes which regulate the production process, but by changes which affect the way products are assessed and analysed. The notified bodies which assess relevant products now have strengthened designation criteria to follow, will be able to conduct joint audits, and will not be required to notify manufacturers of upcoming audits.
This is designed to increase consistency and quality across the board.
Manufacturers will also be required to carry out pre-market checks which have an increased level of scrutiny for high risk (class III or C) devices. All companies require a responsible person as a point of contact for notified bodies and regulators and non EU companies require an authorised representative. Furthermore, the transparency and traceability of devices is to be increased through a central registration system, unique device identification numbers (UDI), and implant cards.
In a concentrated attempt to increase transparency and accessibility, MDR will also make information available to the public through a new database: “the European Database on Medical Devices or EUDAMED.
This database will include information of the devices themselves, on market surveillance, clinical investigation, performance, and safety. This database will also include the UDI for each product so that information can be easily found under a unique signifier.
So, in short, while not every aspect of the new MDR regulation will directly affect the day to day process of production all manufacturers of medical devices will be required to be compliant with the following changes from 26th May 2021. The goal is to increase patient safety, product quality, and public access to information on the medical devices which are at every stage in medical treatment.
The United Kingdom is no longer part of the EU. The UK competent authority has developed its own database for UK companies
How can Polyco Healthline Help?
We're here to provide an accessible and reassuring source of information
If you have any questions regarding the MDR and our products, please do not hesitate to contact our Technical Team via email@example.com or call 020 8443 9090.
For further detailed information - click on the picture below